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Dr Robert G. Scribner (Daly City, Calif). In 1971, Bill
Gore, one of the chemists who developed Teflon in the 1940s
showed to Drs Kelly and Eiseman after a day of skiing at Vail,
Colorado, a necktie made out of a new expanded type of Teflon.
Drs Kelly and Eiseman asked if it could be made into tubes and 5
years later the first prosthetic polytetrafluoroethylene (PTFE)
bridge fistula was placed. It is interesting to note that Dr Dagher,
in that same year, 1976, first reported on the basilic vein transpo-
sition fistula. Unfortunately, early failure rates were unacceptable.
Now, a third of a century later, access surgeons are constructing
more and more autogenous arteriovenous fistulas, largely due to
the dissemination of DOQI guidelines in 1997. In the paper just
presented, the authors conclude that their study demonstrates
significantly improved primary, secondary, and overall functional
patency for the two-stage operation. I have two questions and a
comment.
First, is there a subgroup of patients who would benefit from
the one-stage procedure over the two-stage procedure? Examples
might be early entry of the basilic vein into the brachial vein or
excellent quality of the basilic vein by preoperative vein mapping?
Second, in your paper you recommend that future long-term
investigations should focus on optimal technical considerations in
the two-stage procedure. In your study, all anastamoses were
performed with running 6-0 prolene. Do you think your early
failure rate and perhaps even your primary patency rate could be
improved by selective use of interrupted anastamoses?
Finally, in the paper the authors have detailed several study
limitations. It is retrospective, nonrandomized, and one of the two
institutions in the study performed only one-stage procedure. Also
preoperative vein mapping was not performed in all patients.
Despite these significant limitations, I believe you have presented
reasonable evidence for increased utilization of the two-stage
procedure.
Dr Tyler Reynolds. Thank you for those questions Dr Scrib-
ner. Our study was not powered to determine if there is a subgroup
of patients who would benefit from a one-stage operation. Al-
though it would be tempting to say that large-diameter veinsmight
benefit from a one-stage, we would not be able to recommend that
based on our present data. Your second question addresses the
technical aspects of the anastomosis. We perform all the anastomo-
ses with running 6-0 prolene suture. Selective use of interrupted
sutures may be appropriate in certain situations, although we do
not utilize it, and do not know if such an approach would have
lessened early failures. We agree that a potential weakness of the
study is that routine preoperative veinmapping was not performed.
The minimum basilic vein diameter, as determined intraopera-
tively, is 2.5 mm. We now do perform preoperative vein mapping
for all patients being assessed for a basilic vein fistula. As you
mentioned, one of the institutions performed only one-stage pro-
cedures, but after having analyzed our results, that institution has
switched to the two-stage approach as well.
t
uQuestion 1. Why would one-stage fistulas have such a drop
fter 1 year if injury is indeed due to mechanical injury to the vein?
Dr Christian deVirgilio (Torrance, Calif). We are not really
ure. However, the coronary bypass literature indicates that endo-
copic harvesting of the saphenous vein leads to a higher rate of
raft failure at 18 months compared with open harvesting. So it is
ossible that intraoperative vein injuries or vein ischemia during
he one-stage fistula has the potential of affecting patency beyond
year.
Question 2. The original DOQI guidelines set a benchmark
or fistula placement at 40% now 65% since last year. I think it
mportant to perform preoperative vein mapping on every AV
ccess patient. The first choice obviously is the wrist, the second is
he brachial-cephalic. The latest version of KDOQI now states that
rachial-basilic vein transposition is superior to graft. The other
ssue is selective choosing whether to do one- vs two-stage trans-
osition based on vein size. In our institution, if the vein is 4 mm
r larger, we use a one-stage technique, if between 2 and 4 mm we
se a two-stage technique.We also use an inversion technique. Has
nversion technique been considered in your two institutions?
lso, one of the best indicators of your overall dialysis access
rogram is fistula prevalence. Our approach results in 70% fistula
ate consistently over the last 4 years.
Dr deVirgilio. At Harbor-UCLA, our fistula rate is 85%. We
ave a focus on trying to create fistulas in the vast majority of our
atients. As far as basilic vein diameter is concerned, further studies
ould be needed to see if the patency rates for one-stage proce-
ures are just as good as two stages for basilic veins 4 mm. But
ntil then, our approach is to routinely use a two-stage procedure
egardless of vein diameter. A larger vein might be less prone to
njury, but it may still be at higher risk of kinking during a
ne-stage procedure. In the interest of time, we have time for only
ne more question.
Question 3. One comment, the two-stage does limit the
orbidity of a long incision in a patient that may fail prior to use
or the second stage). My question is related to the definitions of
atency. It is very difficult in a retrospective study to determine
hen a fistula became patent if you define that by cannulation. Do
ou define patency by two-needle cannulation of or by number of
ialysis successions or simply use of the fistula?
Dr Reynolds. We defined functional patency as the ability to
uccessfully perform complete dialysis via two-needle cannulation.
his is clarified in the Methods section. Clearly, patency is always
ifficult to reliably assess retrospectively at any institution. We rely
n clinic visits and local dialysis center records to monitor our
ialysis access patients.
Question 4.My question is regarding cannulation of a trans-
osed vein under a transposed flap. How do you place vein lateral
n your pocket and ensure that vein remains lateral?
Dr deVirgilio. We use a series of 6-0 prolene tacking sutures
o secure the vein at several points to subcutaneous tissue just
nder the skin. This seems to keep the vein from moving.
